6 March 2018 - Today, the U.S. FDA approved Trogarzo (ibalizumab-uiyk), a new type of anti-retroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

The FDA granted this application fast track, priority review and breakthrough therapy designations. Trogarzo also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

Read FDA press release